#Veru

Lead report

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients (NASDAQ:VERU)

Veru (VERU) Q3 FY2026 earnings call: PLATEAU Phase IIb enrollment, Q1 2027 interim catalyst, Novo Wegovy deal, patents to 2044, cash runway—read now.